Back to search

Peptide record

TPDB41019

HB43-mut3 Anticancer standard
13 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB41019
HB43-mut3
Anticancer
Cancer-related peptides
CancerPPD 2.0
standard
No
A 13-aa standard natural anticancer peptide sequence curated from CancerPPD 2.0, with an available 3D structural model.
C-terminal: Amidation
Sequence
FAKLLAKLARRLL-NH2
Physicochemical Analysis
C72H129N21O14
NDCEQGHIMPSTWYV
L
1512.95
12.42
4
0
9
+4
-0.84
0.800
173.08
Mammalian: 1.1 hour Yeast: 3 min E.coli: 2 min
0
0.00
0
Residue Composition
number
3
A
2
R
0
N
0
D
0
C
0
E
0
Q
0
G
0
H
0
I
5
L
2
K
0
M
1
F
0
P
0
S
0
T
0
W
0
Y
0
V
Amino Acid Distribution
A: 3 R: 2 N: 0 D: 0 C: 0 E: 0 Q: 0 G: 0 H: 0 I: 0 L: 5 K: 2 M: 0 F: 1 P: 0 S: 0 T: 0 W: 0 Y: 0 V: 0
Chemical Descriptors
13
C72H129N21O14
1512.95
12.42
+4
-0.84
0.800
Amidation
L
Linear
Free
Anticancer
Synthetic
Evidence Records 4 records
Evidence 1 Activity

Activity

IC50
IC50 = 8 ± 1 µM
Anticancer
8

Target

Colon Cancer
SW-480
Colon

Assay & Model

AlamarBlue assay
24-h

Source & Reference

CancerPPD 2.0
CancerPPD2
2022

Other

Source Activity Label Source Definition
Anticancer
CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.
Evidence 2 Activity

Activity

IC50
IC50 = 9 ± 1 µM
Anticancer
9

Target

Colon Cancer
SW-620
Colon

Assay & Model

AlamarBlue assay
24-h

Source & Reference

CancerPPD 2.0
CancerPPD2
2022
Evidence 3 Activity

Activity

IC50
IC50 = 9 ± 1 µM
Anticancer
9

Target

Colon Cancer
HT-29
Colon

Assay & Model

AlamarBlue assay
24-h

Source & Reference

CancerPPD 2.0
CancerPPD2
2022
Evidence 4 Activity

Activity

75% cell viability at 20 µM
Anticancer

Target

Breast Cancer
MDA-MB-231
Breast

Assay & Model

AlamarBlue assay
Not Available

Source & Reference

CancerPPD 2.0
CancerPPD2
2022